- Home
- SPNS vs NVAX Comparison
SPNS vs NVAX Comparison
Compare SPNS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNS
- NVAX
- Stock Information
- Founded
- SPNS 1982
- NVAX 1987
- Country
- SPNS Israel
- NVAX United States
- Employees
- SPNS N/A
- NVAX N/A
- Industry
- SPNS Computer Software: Prepackaged Software
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPNS Technology
- NVAX Health Care
- Exchange
- SPNS Nasdaq
- NVAX Nasdaq
- Market Cap
- SPNS 1.6B
- NVAX 1.3B
- IPO Year
- SPNS 1992
- NVAX 1995
- Fundamental
- Price
- SPNS $42.77
- NVAX $7.84
- Analyst Decision
- SPNS Hold
- NVAX Hold
- Analyst Count
- SPNS 3
- NVAX 6
- Target Price
- SPNS $31.33
- NVAX $15.00
- AVG Volume (30 Days)
- SPNS 1.9M
- NVAX 8.6M
- Earning Date
- SPNS 08-13-2025
- NVAX 08-06-2025
- Dividend Yield
- SPNS 1.40%
- NVAX N/A
- EPS Growth
- SPNS N/A
- NVAX N/A
- EPS
- SPNS 1.22
- NVAX 2.54
- Revenue
- SPNS $549,037,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- SPNS $8.25
- NVAX $52.02
- Revenue Next Year
- SPNS $6.85
- NVAX N/A
- P/E Ratio
- SPNS $35.05
- NVAX $3.08
- Revenue Growth
- SPNS 3.08
- NVAX 9.22
- 52 Week Low
- SPNS $23.69
- NVAX $5.01
- 52 Week High
- SPNS $42.87
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- SPNS 85.74
- NVAX 48.26
- Support Level
- SPNS $26.14
- NVAX $7.57
- Resistance Level
- SPNS $42.75
- NVAX $10.64
- Average True Range (ATR)
- SPNS 0.55
- NVAX 0.72
- MACD
- SPNS 1.23
- NVAX -0.07
- Stochastic Oscillator
- SPNS 99.43
- NVAX 29.47
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.